Please read the announcement in PDF
news
Transactions under Novonesis’ share buyback program
The Daily Recap
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.More to Read
news
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168) Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and tolerability profile at both doses studied Clinically meaningful and statistically significant fatigue improvements in both dose arms after only 12 weeks underscore the strong therapeutic potential of nasal foralumab in a population with no FDA-approved therapies for na-SPMS BOST
news
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been successfully completed in Colombia, marking a major milestone in the companies' collaboration to bring precision diagnostics to rheumatoid arthritis (RA) patients in Latin America. The strategic partnership brought Scipher's flagship diagnostic, PrismRA ® , to Colombia for the first time th
news
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward profitability €36.3 million in revenue for the first nine months of 2026 from royalties on Ipsen’s sales of Iqirvo® (elafibranor), an increase of 188% year-over-year PBC: Ipsen reported €283m in Iqirvo® net sales in the first nine months of 2026, up 170.8% year-over-year, supporting GENFIT’
news
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® achieved normalization of ALP compared with 23.3% receiving placebo and was generally well tolerated Findings add to growing evidence supporting ALP normalization as an achievable treatment goal in PBC PARIS, FRANCE, 5 NOVEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced toda
news
Osteal Therapeutics Announces Three Scientific Presentations Related to the APEX Clinical Trial Program at the 2026 AAHKS Annual Meeting
Presentations will address 24-month treatment outcomes, systemic antibiotic exposure, and new treatment strategies for recalcitrant periprosthetic joint infection DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing innovative combination drug/device therapies for orthopedic infections, today announced that three scientific presentations evaluating treatment of periprosthetic joint infections with cyclic local antib
news
Genmab Announces Financial Results for the Nine Months of 2026
November 5, 2026 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2026 Highlights Epcoritamab approved in Europe (as TEPKINLY ® ) and Japan (as EPKINLY ® ) in combination with R² for the treatment of adult patients with relapsed or refractory FL Initiation of two new Phase 3 trials for petosemtamab in first- and second-line CRC Genmab revenue increase d 22% compared to the first nine months of 2025 , to $3,238 million “The third quarter of 2026 reinforced the breadth o
news
Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results
Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, announced that it will host a conference call on November 12, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third quarter / first ni
news
Kraig Labs Advances Commercial Spider Silk Production with New Customer Shipments and New Silkworm Research
Kraig Labs First Commercial Spider Silk for High-performance Athletic Apparel Pilot Development Program Kraig Labs First Commercial Spider Silk for High-performance Athletic Apparel Pilot Development Program DENVER, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews )— Kraig Biocraft Laboratories (OTCQB: KBLB) recently shipped its first commercial order of recombinant spider silk yarn to a globally recognized sportswear brand. The September 29 announcement confirmed delivery for a confidential pe
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!